Abiomed CFO to Retire, Replacement Named

Abiomed Inc., a Danvers, Mass.-based maker of heart support technologies, reports that Robert Bowen, the company’s vice president and chief financial officer (CFO) since 2008, will retire from Abiomed next month. Michael Tomsicek will be appointed as vice president and CFO, effective July 15. Bowen, who turns 66 years old this summer, will continue provide a consulting role to facilitate a smooth transition.

“The opportunity to serve as the vice president and chief financial officer of Abiomed has been the most professionally rewarding experience of my 43 year career. For me, I could not envision a better ending. I cannot thank Mike Minogue (Abiomed’s chairman, president and CEO) enough for providing me with the opportunity and the Abiomed team for providing the support necessary to be successful in this role,” said Bowen. “Abiomed will have a tremendous future and I have much personal and professional satisfaction and pride from playing a small part in building the foundation.”

“Bob has served as our CFO for the past seven years as Abiomed has grown revenue greater than three times, market capitalization four times and become GAAP (generally accepted accounting principles) profitable with no debt,” said Minogue. “His leadership, expertise and consistent excellence in fiscal compliance have been instrumental to Abiomed’s success and we are appreciative of his contributions to the company and commitment to patient care We are pleased to welcome Mike Tomsicek to the executive team during this exciting time as Abiomed experiences tremendous growth with the Impella platform. Mike has over 20 years of experience in senior management roles in finance, operations and globalization. We look forward to working with him as Abiomed continues to grow and become the standard of care.”

Tomsicek, 49, joins Abiomed after he most recently served as CFO of Lexington, Mass.-based Cubist Pharmaceuticals. He joined Cubist in 2010 and held a series of roles of increasing responsibility leading finance, investor relations and strategic sourcing through a very dynamic period at the company. Cubist, a global bio-pharmaceutical company, was recently acquired in January 2015 for $9.5 billion by Merck & Co, Inc. Prior to Cubist, Tomsicek spent nearly eight years at General Electric Healthcare, initially as finance manager of its global operations, and then as CFO of two of its largest businesses. Previously, he served in a variety of financial and operational roles at Motorola. Tomsicek holds a bachelor of science degree in engineering and a master of business administration, both from the University of Wisconsin.

“Abiomed has built a revolutionary platform of minimally invasive heart pumps and a world-class business organization. I am excited to step into this role and work closely with Abiomed’s employees and shareholders,” said Tomsicek. “Abiomed is an innovative leader in its space and I look forward to furthering the company’s tradition of commitment to patients, fiscal discipline and growing shareholder value.”